# Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

> **NCT02762578** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 543 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/insulin aspart
- **DRUG:** biphasic insulin aspart

## Key facts

- **NCT ID:** NCT02762578
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-03
- **Primary completion:** 2017-05-19
- **Final completion:** 2017-06-19
- **Target enrollment:** 543 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762578, "Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02762578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*